NewLimit

Epigenetic reprogramming to treat age-related diseases.

newlimit.com

HQ: San Francisco, CA, USA

Biotech

Company research

Public company, workplace, funding, and market signals

Updated Jul 29, 2026

Overview

NewLimit is a South San Francisco biotechnology company building AI- and genomics-driven epigenetic reprogramming medicines to restore youthful function in old cells and extend human healthspan; its lead liver program is moving toward first-in-human studies.

Primary product

Epigenetic reprogramming medicines for aging-related disease, led by a liver-targeted mRNA/LNP reprogramming therapy

Founded

2022

Headquarters

South San Francisco, California, United States

Team size

40-50

Industry

Biotechnology Research

Sub-industry

Epigenetic reprogramming therapeutics

Offices

South San Francisco, California, United States

San Francisco, California, United States

Business model

for-profit biotech

drug discovery and development

platform therapeutics

biopharmaceutical R&D

Funding

Stage

Series C

Total raised

$650M

Latest round

Series C · Jun 2026

Latest amount

$435M

Series C

Jun 2026 · Founders Fund

$435M

Convertible note / extension

Oct 2025 · Eli Lilly and Company

$45M

Additional financing on a $1.62B cap

Oct 2025

$45M

Series B

May 2025 · Kleiner Perkins

$130M

Series A

May 2023 · Dimension Capital

$40M

People & investors

Leadership

Co-founder & CEO

Co-founder

Co-founder

Head of Translation

Head of Computational Sciences

Alex Kim

Head of People

Greg Johnson

Co-founder & Head of Machine Learning

Investors

Work & culture

Mission-focused, optimistic, high-performance, and execution-heavy; values include safety then speed, clear communication, independent thinking, top talent in every seat, and no pure manager roles.

Compensation

Publicly advertises competitive salaries, equity packages, and comprehensive benefits; no salary bands were found.

Benefits

competitive salaries

equity packages

medical insurance

dental insurance

vision insurance

401(k) with up to 4% company match

flexible spending accounts

free EV charging

20 days PTO

15 company holidays

generous new-parent leave

Product & market

Pricing

Not publicly disclosed; expected future therapeutic commercialization via drug sales and/or partnering.

Differentiators

—Uses proprietary AI + genomics discovery engine ('Ambrosia')
—Focuses on epigenetic reprogramming rather than disease-by-disease treatment only
—Lead candidate reportedly reverses age in old human liver cells
—Multi-program platform spanning liver, vascular, and immune systems
—Runs large-scale pooled perturbation screens and functional validation
—Backed by a high-profile founder/investor syndicate

Technology

AI models

functional genomics

single-cell genomics

single-cell perturbation screens

mRNA engineering

lipid nanoparticle (LNP) drug delivery

bioinformatics pipelines

Python

Unix

Docker

NumPy

SciPy

Pandas

AWS

GCP

Azure

Google Cloud

Git

JMP

Competitors

Altos Labs

Retro Biosciences

Insitro

Evotec

DNAnexus

Isomorphic Labs

Scale & contact

Estimated revenue

≈US$4.6M–12.8M estimated annual revenue (public sources vary)

Estimated monthly visits

10.4K

Traffic estimate as of Jun 2026

415-603-9539

Latest news

NewLimit raises $435m for liver trials, and other financings

pharmaphorum · Jun 2026

Summarizes the financing and notes the earlier $40M Series A and $130M Series B plus the company’s path toward the clinic.

NewLimit snags $435M after seeing age reversal in human liver cells

BioSpace · Jun 2026

Describes the breakthrough prototype medicine, the new funding, and the company’s acceleration toward human testing.

NewLimit raises $435M led by Founders Fund to bring longevity medicines to human trials

NewLimit blog · Jun 2026

Official announcement of the $435M Series C led by Founders Fund, with participation from Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital, and others. The company said the new capital accelerates its first human clinical trial timeline to 2027.

Anti-aging biotech NewLimit nabs $435M to rejuvenate old cells

Fierce Biotech · Jun 2026

Highlights the lead liver candidate, the push toward phase 1 next year, and work on vascular and immune programs.

Anti-aging biotech NewLimit raises $435M at $3B+ valuation

Endpoints News · Jun 2026

Covers the Series C, the faster-than-expected path to clinic, and the company’s first anti-aging drug candidate for liver cells.

Jobs and careers at NewLimit

14 jobs at NewLimit

Senior/Research Associate, Single Cell Technology

On-site

Single Cell Technology

South San Francisco, CA; South San Francisco, California, United States

4d ago

On-site

Full-time